

PATENT
2815-0236P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Thomas J. JENTSCH Conf.: Unknown
Appl. No.: NEW (Div. of 09/590,304) Group: Unknown
Filed: September 11, 2003 Examiner: Unassigned
For: NOVEL POTASSIUM CHANNELS AND GENES
ENCODING THESE POTASSIUM CHANNELS

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

September 15, 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).
09/590,304

U.S. Filing Date(s)
June 9, 2000

III. FEES

This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Gerald M. Murphy, Jr., #28,977

^{KLR}
GMM/KLR/jeb
2815-0236P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s): ☒ PTO-1449(s)

☐ References

☐ Foreign Search Report

☐ Other:

(Rev. 04/29/03)

Form PTO-1449				ATTY DOCKET NO. 2815-0236P		APPLICATION NO. NEW (Div. of 09/590,304)		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				APPLICANT Thomas J. JENTSCH				
				FILING DATE September 11, 2003		GROUP Unknown		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
	US							
	US							
FOREIGN PATENT DOCUMENTS								
	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	WO	01/70759	A1	2001-09-27	PCT			
	WO	01/70811	A1	2001-09-27	PCT			
	WO	01/92526	A1	2001-12-06	PCT			
	WO	99/07832		1999-02-18	PCT			
	WO	99/21875		1999-05-06	PCT			
	WO	99/31232		1999-06-24	PCT			
	WO	00/44786		2000-08-03	PCT			
	WO	00/61606		2000-10-19	PCT			
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.								
Lerche et al., J. Biol. Chem., April 27, 2000, Abstract (PMID: 10787416).								
Schroder et al., J. Biol. Chem., May 17, 2000, Abstract (PMID:10816588).								
Christian Kubisch et al., Cell, February 5, 1999, Vol. 96, pages 437-446.								
Björn C. Schroeder et al., Nature, December 17, 1998, Vol. 396, pages 687-690.								
Q. Wang et al., Nature Genetics, January 1996, Vol. 12, pages 17-23.								
Christian Biervert et al., Science, January 16, 1998, Vol. 279, pages 403-406.								
S. William Tam et al., "Linopirdine A Depolarization-Activated Releaser of Transmitters for Treatment of Dementia." Lilly Tang et al. eds., in <u>Neurochemistry in Clinical Application</u> , 1995, pp. 47-56.								
Skolnick et al., Trends in Biotech., 18(1):34-39, 2000.								
Jobling et al., Mol. Microbiol., 1991, 5(7):1755-67.								
Sambrook et al., Cold Spring Harbor Labs, 1989, pp. 9.47-9.51 and 11.48-11.49.								
EXAMINER					DATE CONSIDERED			
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>								

GMM/KLR/jeb